Christopher Chang

Christopher Chang

Auto-generated profile, based on publicly available information

Christopher Chang

Joe DiMaggio Children's Hospital, Hollywood, FL

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Autoimmunity
Verified
Journal Article
Closed access
YYYongshi Yang
Yongshi Yang
FPFujun Peng
Fujun Peng
RWRunsheng Wang
Runsheng Wang
KGKai Guan
Kai Guan
TJTaijiao Jiang
Taijiao Jiang
CCChristopher Chang
Christopher Chang

23 May 2020
Verified
Book Chapter
Closed access
PDF file
LZLian Zhang
Lian Zhang
QLQianjin Lu
Qianjin Lu
CCChristopher Chang
Christopher Chang

1 June 2020 in Journal of Autoimmunity
Verified
Journal Article
Closed access
CCChristopher Chang
Christopher Chang
AGAdam Greenspan
Adam Greenspan
MGM Eric Gershwin
M Eric Gershwin

1 August 2020 in Journal of Autoimmunity
Verified
Journal Article
Closed access
GLGuoping Li
Guoping Li
XHXiang He
Xiang He
LZLei Zhang
Lei Zhang
QRQin Ran
Qin Ran
JWJunyi Wang
Junyi Wang
CCChristopher Chang
Christopher Chang

1 August 2020 in Journal of Autoimmunity
Verified
Journal Article
Closed access
YSYing Sun
Ying Sun
YDYanli Dong
Yanli Dong
LWLifeng Wang
Lifeng Wang
HXHuan Xie
Huan Xie
BLBaosen Li
Baosen Li
FWFusheng Wang
Fusheng Wang

22 February 2021 in International Reviews of Immunology
Verified
Journal Article
Closed access
YQYifan Que
Yifan Que
CHChao Hu
Chao Hu
KWKun Wan
Kun Wan
PHPeng Hu
Peng Hu
RWRunsheng Wang
Runsheng Wang
GXGuogang Xu
Guogang Xu
The coronavirus disease 2019 (COVID-19) triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) erupted in Hubei Province of China in December 2019 and has become a pandemic. Severe COVID-19 patients who suffer from acute respiratory distress syndrome (ARDS) and multi-organ dysfunction have high mortality. Several studies have shown that this is closely related to the cytokine release syndrome (CRS), often loosely referred to as cytokine storm. IL-6 is one of the key factors and its level is positively correlated with the severity of the disease. The molecular mechanisms for CRS in COVID-19 are related to the effects of the S-protein and N-protein of the virus and its ability to trigger NF-κB activation by disabling the inhibitory component IκB. This leads to activation of immune cells and the secretion of proinflammatory cytokines such as IL-6 and TNF-α. Other mechanisms related to IL-6 include its interaction with GM-CSF and interferon responses. The pivotal role of IL-6 makes it a target for therapeutic agents and studies on tocilizumab are already ongoing. Other possible targets of treating CRS in COVID-19 include IL-1β and TNF-α. Recently, reports of a CRS like illness called multisystem inflammatory syndrome in children (MIS-C) in children have surfaced, with a variable presentation which in some cases resembles Kawasaki disease. It is likely that the immunological derangement and cytokine release occurring in COVID-19 cases is variable, or on a spectrum, that can potentially be governed by genetic factors. Currently, there are no approved biological modulators for the treatment of COVID-19, but the urgency of the pandemic has led to numerous clinical trials worldwide. Ultimately, there is great promise that an anti-inflammatory modulator targeting a cytokine storm effect may prove to be very beneficial in reducing morbidity and mortality in COVID-19 patients.